InterMune, Inc. (ITMN) Reports Second Quarter 2013 Financial Results and Business Highlights
7/25/2013 6:36:46 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
InterMune reported Esbriet® (pirfenidone) revenue in the second quarter of 2013 of $14.4 million, compared with $5.5 million of Esbriet revenue in the same quarter of 2012. Sequentially, Esbriet revenue in the second quarter of 2013 increased 37 percent from $10.5 million in the first quarter of 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by